NL-OMON56823已完成不适用
Holter (for) Risk Recognition & Conversion (of) life-threatening events (into survival) - Horracles
Sorin Group Nederland NV0 个研究点目标入组 195 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Criteria for prophylactic ICD according to guidelines in patients with reduced LVEF
- •- Written informed consent
- •- Scheduled for implant of a PARADYM 8550 or PARADYM 9550
排除标准
- •1. Under the age of 18 years old
- •2. Presence of a permanent pacemaker or previous ICD
- •3. Permanent AF
- •4. NYHA IV
- •5. Within 8 weeks of infarction or within 3 months of coronary revascularization
- •6. Patient requiring permanent amiodarone or antiarrhythmic drugs.
- •7. Specific familial or genetic based arrhythmias.
- •8. ARVC, HCM, or severe valvular disease
- •9. CRT indication (European guidelines)
- •10. Renal hemodialysis
- •11. Recipient of cardiac transplant
- •12. Pregnancy
- •13. Advanced malignancy
研究者
相似试验
进行中（未招募）
不适用
Development of a tool for effective comparisons of breast cancer survival between hospitalsCancerBreast cancerISRCTN69229101Karolinska University Hospital45,441
招募中
不适用
Quality assessment of report in clinical biochemistry laboratory using Sigma scale.CTRI/2017/02/007756Father Muller Medical College institutional grants committee100
招募中
不适用
*The PreRisk calculator in suspected or confirmed preeclampsia: A new tool to safely reduce the number of unnecessary admissions*NL-OMON48687Erasmus MC, Universitair Medisch Centrum Rotterdam864
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 19.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-NLBristol-Myers Squibb International Corporation80
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-DEBristol-Myers Squibb International Corporation72